https://wikimd.com/index.php?action=history&feed=atom&title=RegdanvimabRegdanvimab - Revision history2026-04-06T07:53:55ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.com/index.php?title=Regdanvimab&diff=5168949&oldid=prevPrab: CSV import2024-02-20T00:50:05Z<p>CSV import</p>
<p><b>New page</b></p><div>'''Regdanvimab''' is a monoclonal antibody medication that is used for the treatment of COVID-19. It was developed by the South Korean company Celltrion.<br />
<br />
==Etymology==<br />
The name "Regdanvimab" is derived from the words "regulation", "antiviral", and "monoclonal antibody". The "reg" in "Regdanvimab" refers to the drug's ability to regulate the immune response to the virus, the "danvi" is a reference to its antiviral properties, and the "mab" at the end of the name is a common suffix for monoclonal antibodies.<br />
<br />
==Medical Uses==<br />
Regdanvimab is used for the treatment of mild to moderate [[COVID-19]] in adults who are at high risk of progressing to severe COVID-19. It is administered via intravenous infusion.<br />
<br />
==Mechanism of Action==<br />
Regdanvimab is a monoclonal antibody that targets the spike protein of SARS-CoV-2, the virus that causes COVID-19. By binding to the spike protein, it prevents the virus from entering human cells, thereby inhibiting viral replication.<br />
<br />
==Development and Approval==<br />
Regdanvimab was developed by the South Korean company [[Celltrion]]. In February 2021, it was granted conditional marketing authorization by the Ministry of Food and Drug Safety (MFDS) in South Korea for the treatment of high-risk patients with mild to moderate COVID-19.<br />
<br />
==See Also==<br />
* [[Monoclonal antibodies]]<br />
* [[COVID-19 treatment]]<br />
* [[Celltrion]]<br />
<br />
[[Category:Monoclonal antibodies]]<br />
[[Category:COVID-19 treatment]]<br />
[[Category:Celltrion]]<br />
<br />
{{stub}}</div>Prab